The compound discussed commercially is a synthetic research peptide
A 2022 meta-analysis of 37 RCTs involving 3,048 patients, published in Frontiers in Pharmacology , found that berberine significantly reduced fasting plasma glucose by an average of 0.82 mmol/L and HbA1c by 0.63% without significantly increasing hypoglycemia risk
Recent evidence also suggests potential benefits in peripheral artery disease, which was studied in the STRIDE trial, and neurodegenerative disorders, such as ongoing research in Alzheimers disease (EVOKE and EVOKE+ trials)
*To offset the potential increase in TMAO, Huberman uses 600 mg garlic capsules along with Alpha GPC
Disruption of astroglial interlaminar processes in Alzheimers disease
Following the ingestion of carbohydrates and fats, GLP-1 is released and exerts multiple physiological effects essential for maintaining glucose homeostasis ( Metabolically, GLP-1 acts through G protein-coupled receptors to improve insulin sensitivity in muscle and adipose tissues while enhancing -cell function by promoting proliferation and inhibiting apoptosis (see Figure 3)